Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

What is dementia?

music therapy1 - risk of stroke1 - neuronal activity1 - prevent alzheimer's1 - beta amyloid3 - beta amyloid plaques1 - university of southern california2 - alzheimer's signs1 - igf-11 - decline in cognitive functioning1 - glucose metabolism2 - amyloid β1 - amyloid1 - abstract thinking1 - parkinson's patients5 - apoe gene3 - alpha-synuclein diseases1 - journal of clinical nursing1 - mental stimulation1 - sleep disturbances1 - haloperidol2 - symptoms of alzheimer's2 - hormone therapy1 - microrna1 - hippocampal atrophy1 - delay dementia1 - care or dementia1 - beta-blocker drugs1 - alzheimer's warning signs1 - beta-amyloid protein1 -